Fundraise

JunFuture BioMedicine raises $4.5M to industrialise medical fluorocarbon

What's the deal? JunFuture BioMedicineDealroom has a profile for this one. Try Dealroom →, a Jiangsu-based developer of medical fluorocarbon materials, has raised US$4.13M in an early-stage Pre-A round. The funding came from Taizhou Huayin Jintou and the Taizhou Angel Investment Fund.

What's the endgame? Founded in 2021 and headquartered in Nanjing, the company is building four fluorocarbon drug platforms — injectable, ophthalmic, topical, and inhaled — alongside upstream raw-material supply. Fluorocarbons are chemically inert and dissolve large amounts of gas, making them useful for treating hypoxia, oxidative stress, and tissue protection.

Where's the money going? The round will fund core pipeline research and development plus GMP production capacity and regulatory filings for its first fluorocarbon active-ingredient and excipient project in Taizhou.

Why Taizhou? Founder Cheng Yuhao said the company chose the Taizhou Medical High-Tech Zone for its concentrated production base and services that help firms secure approvals and start production quickly. He said JunFuture aims to "quickly consolidate" its overseas capability on the raw-material side. (translated from Chinese)

Why now? JunFuture is positioning against European and US incumbents such as NuvOX, Novaliq, and FluoronDealroom has a profile for this one. Try Dealroom →. Investor Huayin Jintou said the company fills a local gap in high-end medical fluorocarbon and uses an exclusive continuous-flow synthesis process to build a domestic production base.

What could go wrong? The disclosed plans do not mean any product is approved or commercialised. GMP start-up, registration progress, and customer validation will be the real tests of its competitiveness.

The signal: Medical fluorocarbon is moving into commercial products — Hengrui and Novaliq's perfluorohexyloctane eye drops won Chinese approval in 2025. JunFuture's bet is to link raw-material manufacturing with downstream drugs and devices, slotting into a domestic supply chain where overseas firms have long dominated.

Read more: vbdata.cn

Image credit: Generated with Gemini

More top stories